<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504803</url>
  </required_header>
  <id_info>
    <org_study_id>TJB0601</org_study_id>
    <nct_id>NCT00504803</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease</brief_title>
  <official_title>Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host&#xD;
      Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative&#xD;
      Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day-100 incidence of non-relapse mortality</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSC co-infusion with either HLA-mismatched PBSC or cord blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mesenchymal stem cell infusion</intervention_name>
    <description>Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mesenchymal stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        V.1. Patients&#xD;
&#xD;
        V.1.1. Diseases&#xD;
&#xD;
        Hematological malignancies confirmed histologically and not rapidly progressing:&#xD;
&#xD;
          -  AML in CR;&#xD;
&#xD;
          -  ALL in CR;&#xD;
&#xD;
          -  CML unresponsive/intolerant to Imatinib but not in blast crisis;&#xD;
&#xD;
          -  Other myeloproliferative disorders not in blast crisis and not with extensive&#xD;
             myelofibrosis;&#xD;
&#xD;
          -  MDS with &lt; 5% blasts;&#xD;
&#xD;
          -  Multiple myeloma;&#xD;
&#xD;
          -  CLL;&#xD;
&#xD;
          -  Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);&#xD;
&#xD;
          -  Hodgkin's disease.&#xD;
&#xD;
        V.1.2. Clinical situations&#xD;
&#xD;
          -  Theoretical indication for a standard allo-transplant, but not feasible because:&#xD;
&#xD;
               -  Age &gt; 55 yrs;&#xD;
&#xD;
               -  Unacceptable end organ performance;&#xD;
&#xD;
               -  Patient's refusal.&#xD;
&#xD;
          -  Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months&#xD;
             after standard autotransplant.&#xD;
&#xD;
        V.1.3. Other inclusion criteria&#xD;
&#xD;
          -  Male or female; fertile female patients must use a reliable contraception method;&#xD;
&#xD;
          -  Age &lt; 75 yrs.&#xD;
&#xD;
          -  Informed consent given by patient or his/her guardian if of minor age.&#xD;
&#xD;
        V.1.4. Exclusion criteria&#xD;
&#xD;
          -  Any condition not fulfilling inclusion criteria;&#xD;
&#xD;
          -  HIV positive;&#xD;
&#xD;
          -  Terminal organ failure, except for renal failure (dialysis acceptable);&#xD;
&#xD;
          -  Uncontrolled infection, arrhythmia or hypertension;&#xD;
&#xD;
          -  Previous radiation therapy precluding the use of 2 Gy TBI;&#xD;
&#xD;
          -  HLA-identical donor.&#xD;
&#xD;
        V.2. PBSC donors&#xD;
&#xD;
        V.2.1. Inclusion criteria&#xD;
&#xD;
          -  Related to the recipient (sibling, parent or child) or unrelated;&#xD;
&#xD;
          -  Male or female;&#xD;
&#xD;
          -  Weight &gt; 15 Kg (because of leukapheresis);&#xD;
&#xD;
          -  Fulfills generally accepted criteria for allogeneic PBSC donation;&#xD;
&#xD;
          -  Informed consent given by donor or his/her guardian if of minor age, as per donor&#xD;
             center standard procedures.&#xD;
&#xD;
        V.2.2. Exclusion criteria&#xD;
&#xD;
          -  Any condition not fulfilling inclusion criteria;&#xD;
&#xD;
          -  HIV positive;&#xD;
&#xD;
          -  Unable to undergo leukapheresis because of poor vein access or other reasons.&#xD;
&#xD;
        V.2.3. HLA matching&#xD;
&#xD;
        Related or unrelated donors who have 1-2 HLA mismatches, as either :&#xD;
&#xD;
          -  One antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1&#xD;
&#xD;
          -  One allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1&#xD;
&#xD;
          -  Two allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1&#xD;
&#xD;
          -  One antigenic mismatch + 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1.&#xD;
&#xD;
          -  One antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B or -C&#xD;
             or -DRB1&#xD;
&#xD;
        V.3. Cord blood unit&#xD;
&#xD;
        Banked cord blood units will be used if they fulfill the following criteria:&#xD;
&#xD;
          -  No more than 2/6 HLA mismatches (antigenic mismatch at HLA-A or HLA-B or allelic&#xD;
             mismatch at HLA-DRB1)&#xD;
&#xD;
          -  &gt; 2.5 x 107 TNC/kg&#xD;
&#xD;
          -  Standard validation by FACT/Netcord criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Baron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Beguin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chantal Lechanteur, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Etienne Baudoux, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evelyne Willems, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <last_update_submitted>September 1, 2011</last_update_submitted>
  <last_update_submitted_qc>September 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Yves Beguin</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>HCT, nonmyeloablative, mesenchymal stem cells, GVHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

